Evaluation of inosin-5′-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus

T. Maiguma, T. Yosida, K. Otsubo, Yasuhiro Okabe, A. Sugitani, M. Tanaka, R. Oishi, D. Teshima

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: The aim of this study was to identify a target range for inosin-5′-monophosphate dehydrogenase (IMPDH) activity in maintenance therapy with tacrolimus (TCL), and to apply the measurement of IMPDH activity to the therapeutic drug monitoring for mycophenolate mofetil (MMF). Methods: Eleven patients with renal transplants and 10 healthy volunteers were investigated. All patients were treated with a combination of TCL, steroid and MMF for 2 months after transplantation, and were in stable and good condition. IMPDH activity was determined indirectly by measuring xanthosine 5′-monophophate in cell lysates supplemented with IMP and -nicotine adenine dinucleotide using an high-performance liquid chromatography (HPLC) method. Results: The within-run reproducibility of the assay was excellent, with relative standard deviation (RSD) values of 0·41-4·08%. The mean differences between the spiked concentrations of xanthosine 5′- monophophate and their real values (mean relative errors; MREs) were within a range of 2·66-8·89%, showing good accuracy. The interday RSD values were 1·51-6·12% and MREs ranged from 2·10% to 8·89%. Cell lysates showed a 5-6 nmolL IC50 mycophenolic acid (MPA) concentration. TCL, cyclosporine and prednisolone did not affect IMPDH activity. The peak MPA concentration was achieved at 1 h after dosing. IMPDH activity decreased to 75% and 67% at 1 and 2 h after dosing respectively. Therefore, the inhibition rates of MPA against IMPDH activity may be adequate at 25-40% in TCL maintenance therapy. Conclusion: Inosin-5′-monophosphate dehydrogenase activity in cell lysates could be reliably determined by HPLC. A 25-40% inhibition of IMPDH activity may be an appropriate range for preventing rejection with MPF but this requires further validation using larger studies with harder outcomes such as rejection episodes.

Original languageEnglish
Pages (from-to)79-85
Number of pages7
JournalJournal of Clinical Pharmacy and Therapeutics
Volume35
Issue number1
DOIs
Publication statusPublished - Feb 1 2010

Fingerprint

Tacrolimus
Mycophenolic Acid
Oxidoreductases
Therapeutics
High Pressure Liquid Chromatography
Inosine Monophosphate
Drug Monitoring
Adenine
Prednisolone
Nicotine
Cyclosporine
Inhibitory Concentration 50
Healthy Volunteers
Transplantation
Steroids
Transplants
Kidney

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Evaluation of inosin-5′-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus. / Maiguma, T.; Yosida, T.; Otsubo, K.; Okabe, Yasuhiro; Sugitani, A.; Tanaka, M.; Oishi, R.; Teshima, D.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 35, No. 1, 01.02.2010, p. 79-85.

Research output: Contribution to journalArticle

Maiguma, T. ; Yosida, T. ; Otsubo, K. ; Okabe, Yasuhiro ; Sugitani, A. ; Tanaka, M. ; Oishi, R. ; Teshima, D. / Evaluation of inosin-5′-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus. In: Journal of Clinical Pharmacy and Therapeutics. 2010 ; Vol. 35, No. 1. pp. 79-85.
@article{cc05d4d7cf4a4c7c9ebdfeff3ef27d41,
title = "Evaluation of inosin-5′-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus",
abstract = "Objectives: The aim of this study was to identify a target range for inosin-5′-monophosphate dehydrogenase (IMPDH) activity in maintenance therapy with tacrolimus (TCL), and to apply the measurement of IMPDH activity to the therapeutic drug monitoring for mycophenolate mofetil (MMF). Methods: Eleven patients with renal transplants and 10 healthy volunteers were investigated. All patients were treated with a combination of TCL, steroid and MMF for 2 months after transplantation, and were in stable and good condition. IMPDH activity was determined indirectly by measuring xanthosine 5′-monophophate in cell lysates supplemented with IMP and -nicotine adenine dinucleotide using an high-performance liquid chromatography (HPLC) method. Results: The within-run reproducibility of the assay was excellent, with relative standard deviation (RSD) values of 0·41-4·08{\%}. The mean differences between the spiked concentrations of xanthosine 5′- monophophate and their real values (mean relative errors; MREs) were within a range of 2·66-8·89{\%}, showing good accuracy. The interday RSD values were 1·51-6·12{\%} and MREs ranged from 2·10{\%} to 8·89{\%}. Cell lysates showed a 5-6 nmolL IC50 mycophenolic acid (MPA) concentration. TCL, cyclosporine and prednisolone did not affect IMPDH activity. The peak MPA concentration was achieved at 1 h after dosing. IMPDH activity decreased to 75{\%} and 67{\%} at 1 and 2 h after dosing respectively. Therefore, the inhibition rates of MPA against IMPDH activity may be adequate at 25-40{\%} in TCL maintenance therapy. Conclusion: Inosin-5′-monophosphate dehydrogenase activity in cell lysates could be reliably determined by HPLC. A 25-40{\%} inhibition of IMPDH activity may be an appropriate range for preventing rejection with MPF but this requires further validation using larger studies with harder outcomes such as rejection episodes.",
author = "T. Maiguma and T. Yosida and K. Otsubo and Yasuhiro Okabe and A. Sugitani and M. Tanaka and R. Oishi and D. Teshima",
year = "2010",
month = "2",
day = "1",
doi = "10.1111/j.1365-2710.2009.01072.x",
language = "English",
volume = "35",
pages = "79--85",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Evaluation of inosin-5′-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus

AU - Maiguma, T.

AU - Yosida, T.

AU - Otsubo, K.

AU - Okabe, Yasuhiro

AU - Sugitani, A.

AU - Tanaka, M.

AU - Oishi, R.

AU - Teshima, D.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Objectives: The aim of this study was to identify a target range for inosin-5′-monophosphate dehydrogenase (IMPDH) activity in maintenance therapy with tacrolimus (TCL), and to apply the measurement of IMPDH activity to the therapeutic drug monitoring for mycophenolate mofetil (MMF). Methods: Eleven patients with renal transplants and 10 healthy volunteers were investigated. All patients were treated with a combination of TCL, steroid and MMF for 2 months after transplantation, and were in stable and good condition. IMPDH activity was determined indirectly by measuring xanthosine 5′-monophophate in cell lysates supplemented with IMP and -nicotine adenine dinucleotide using an high-performance liquid chromatography (HPLC) method. Results: The within-run reproducibility of the assay was excellent, with relative standard deviation (RSD) values of 0·41-4·08%. The mean differences between the spiked concentrations of xanthosine 5′- monophophate and their real values (mean relative errors; MREs) were within a range of 2·66-8·89%, showing good accuracy. The interday RSD values were 1·51-6·12% and MREs ranged from 2·10% to 8·89%. Cell lysates showed a 5-6 nmolL IC50 mycophenolic acid (MPA) concentration. TCL, cyclosporine and prednisolone did not affect IMPDH activity. The peak MPA concentration was achieved at 1 h after dosing. IMPDH activity decreased to 75% and 67% at 1 and 2 h after dosing respectively. Therefore, the inhibition rates of MPA against IMPDH activity may be adequate at 25-40% in TCL maintenance therapy. Conclusion: Inosin-5′-monophosphate dehydrogenase activity in cell lysates could be reliably determined by HPLC. A 25-40% inhibition of IMPDH activity may be an appropriate range for preventing rejection with MPF but this requires further validation using larger studies with harder outcomes such as rejection episodes.

AB - Objectives: The aim of this study was to identify a target range for inosin-5′-monophosphate dehydrogenase (IMPDH) activity in maintenance therapy with tacrolimus (TCL), and to apply the measurement of IMPDH activity to the therapeutic drug monitoring for mycophenolate mofetil (MMF). Methods: Eleven patients with renal transplants and 10 healthy volunteers were investigated. All patients were treated with a combination of TCL, steroid and MMF for 2 months after transplantation, and were in stable and good condition. IMPDH activity was determined indirectly by measuring xanthosine 5′-monophophate in cell lysates supplemented with IMP and -nicotine adenine dinucleotide using an high-performance liquid chromatography (HPLC) method. Results: The within-run reproducibility of the assay was excellent, with relative standard deviation (RSD) values of 0·41-4·08%. The mean differences between the spiked concentrations of xanthosine 5′- monophophate and their real values (mean relative errors; MREs) were within a range of 2·66-8·89%, showing good accuracy. The interday RSD values were 1·51-6·12% and MREs ranged from 2·10% to 8·89%. Cell lysates showed a 5-6 nmolL IC50 mycophenolic acid (MPA) concentration. TCL, cyclosporine and prednisolone did not affect IMPDH activity. The peak MPA concentration was achieved at 1 h after dosing. IMPDH activity decreased to 75% and 67% at 1 and 2 h after dosing respectively. Therefore, the inhibition rates of MPA against IMPDH activity may be adequate at 25-40% in TCL maintenance therapy. Conclusion: Inosin-5′-monophosphate dehydrogenase activity in cell lysates could be reliably determined by HPLC. A 25-40% inhibition of IMPDH activity may be an appropriate range for preventing rejection with MPF but this requires further validation using larger studies with harder outcomes such as rejection episodes.

UR - http://www.scopus.com/inward/record.url?scp=74349085408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74349085408&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2710.2009.01072.x

DO - 10.1111/j.1365-2710.2009.01072.x

M3 - Article

C2 - 20175815

AN - SCOPUS:74349085408

VL - 35

SP - 79

EP - 85

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 1

ER -